Paper - WANFANG MED ONLINE

You Position: Home > Paper

Management of Cutaneous Lupus Erythematosus

( views:310, downloads:116 )

Author:: No author available

Journal Title:: INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY

Issue:: 6

DOI:: 10.3760/cma.j.issn.1673-4173.2006.06.004

Key Word:: 红斑狼疮,皮肤;治疗

Abstract：皮肤型红斑狼疮是红斑狼疮病谱中相对较轻的一型,治疗上有别于系统性红斑狼疮,目前尚无固定的治疗模式.局部外用糖皮质激素是广泛采用的治疗手段之一,对各种皮肤型红斑狼疮均有效.较新型的外用制剂如他克莫司及吡美莫司,主要用于治疗对糖皮质激素和常规药物无效的皮肤型红斑狼疮.对外用药物治疗无效的皮损,可选择皮损内注射糖皮质激素,以快速发挥抗炎和免疫抑制作用.细胞毒药物和沙利度胺主要治疗复发或难治性皮肤型红斑狼疮.激光及光疗也能有效改善皮肤型红斑狼疮的皮损.

Reference

[1]D P, McCauliffe.Cutaneous lupus erythematosus.[J].2001,20(1).
[2]Pisoni CN,Sanchez FJ,Sepp NT,etc.Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil.[J].2005,23(3).
[3]A, Kuhn,D, Richter-Hintz,C, Oslislo,etc.Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases.[J].2000,136.
[4]J. Wenzel,S. Brähler,R. Bauer,etc.Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients[J].2005,153(1).
[5]Fabbri P.,Cardinali C.,Giomi B.,etc.Cutaneous Lupus Erythematosus: Diagnosis and Management[J].2003,4(7).
[6]Ochonisky S,Revuz J,Poli F,etc.Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients.[J].2002,119(5).
[7]Anna, Wozniacka,Daniel P, McCauliffe.Optimal use of antimalarials in treating cutaneous lupus erythematosus.[J].2005,6(1).
[8]Callen JP.Management of 'refractory' skin disease in patients with lupus erythematosus.[J].2005,19(5).
[9]Iaccarino L,Briani C,Ghirardello A,etc.Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.[J].2005,38(7).
[10]Tamara Salam, Housman,Joseph L, Jorizzo,Martha A, McCarty,etc.Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.[J].2003,139.
[11]S. Schanz,A. Ulmer,G. Rassner,etc.Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil[J].2002,147(1).
[12]Millard T P,Hawk J LM.Ultraviolet therapy in lupus[J].2001,10(3).
[13]D'Cruz DP,Hughes GR,Sangle S,etc.Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.[J].2004,43(11).
[14]J.J. Wu,D.B. Huang,K.R. Pang,etc.Thalidomide: dermatological indications, mechanisms of action and side‐effects[J].2005,153(2).
[15]R, Neri,M, Mosca,E, Bernacchi,etc.A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone.[J].1999,8.
[16]M, Goodfield,K, Davison,K, Bowden.Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE).[J].2004,15(1).
[17]Nour Eldin O,Rijhwani M,Al Mutairi N.Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy.[J].2005,32(6).
[18]Belmar P,Baniandres O,Boixeda P,etc.Treatment of lupus erythematosus with pulsed dye laser.[J].2003,32(4).
[19]Barba Gomez F,Hernandez Torres M,Salazar Paramo M,etc.Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus.[J].2005,44(12).
[20]Maria J. Cuadrado,Yousuf Karim,Giovanni Sanna,etc.Thalidomide for the treatment of resistant cutaneous lupus: Efficacy and safety of different therapeutic regimens[J].2005,118(3).
[21]Wallace D J.Antimalarials—the ‘real‘ advance in lupus[J].2001,10(6).